VBI Vaccines Inc.
$0.07-50.87%($-0.07)
TickerSpark Score
57/100
73
Valuation
40
Profitability
100
Growth
44
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VBIV research report →
52-Week Range1% of range
Low $0.06
Current $0.07
High $1.35
Companywww.vbivaccines.com
VBI Vaccines Inc. , a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine.
- CEO
- Jeffery R. Baxter FCMA
- IPO
- 2010
- Employees
- 131
- HQ
- Cambridge, MA, US
Price Chart
-98.39% · this period
Valuation
- Market Cap
- $1.87M
- P/E
- -0.01
- P/S
- 0.22
- P/B
- 0.14
- EV/EBITDA
- -0.38
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -66.98%
- Op Margin
- -637.08%
- Net Margin
- -1069.29%
- ROE
- -258.99%
- ROIC
- -86.51%
Growth & Income
- Revenue
- $8.68M · 702.40%
- Net Income
- $-92,836,000 · 34.14%
- EPS
- $-5.96 · 63.59%
- Op Income
- $-55,311,000
- FCF YoY
- 20.87%
Performance & Tape
- 52W High
- $1.35
- 52W Low
- $0.06
- 50D MA
- $0.57
- 200D MA
- $0.60
- Beta
- 2.17
- Avg Volume
- 8.39M
Get TickerSpark's AI analysis on VBIV
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 27, 23 | DeWilde Michel | other | 35,000 |
| Jul 27, 23 | Braga Damian | other | 35,000 |
| Jul 27, 23 | Baxter Jeff | other | 70,000 |
| Jul 27, 23 | Cordeiro Joanne | other | 35,000 |
| Jul 27, 23 | Beattie Nell | other | 52,500 |
| Jul 27, 23 | HIMES VAUGHN B | other | 35,000 |
| Jul 27, 23 | Mazaltov Avi | other | 52,500 |
| Jul 27, 23 | Diaz-Mitoma Francisco | other | 52,500 |
| Jul 27, 23 | GILLIS STEVEN | other | 52,500 |
| Jul 27, 23 | Dillman John Robert | other | 52,500 |
Our VBIV Coverage
We haven't published any research on VBIV yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VBIV Report →Similar Companies
ONCSQ+0.00%
OncoSec Medical Incorporated
$0.00
FRES-23.42%
Fresh2 Group Limited
$0.85
MTP-18.50%
Midatech Pharma plc
$0.29
PTE-0.82%
PolarityTE, Inc.
$0.24
NBSE-1.56%
NeuBase Therapeutics, Inc.
$0.38
ONCT-24.12%
Oncternal Therapeutics, Inc.
$0.53
CUTR+0.00%
Cutera, Inc.
$0.10
GMVD+1.38%
G Medical Innovations Holdings Ltd
$0.18